{
    "info": {
        "nct_id": "NCT05254184",
        "official_title": "Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Advanced KRAS Mutated Non-Small Cell Lung Cancer",
        "inclusion_criteria": "* Histologically- or cytologically-proven adenocarcinoma of the lung deemed to be locally advanced/unresectable or metastatic as per American Joint Committee on Cancer (AJCC) version 8, who has not received prior therapy for this stage of disease.\n\n  • Prior therapy for early stage NSCLC allowed. Progressive disease after at least 6 months of anti-programmed death (PD) ligand therapy (anti-PD-L1 therapy) (i.e. Durvalumab) for Stage III disease is allowed.\n* Must have tumor lesions amenable to repeated biopsy, and patient's acceptance to have a tumor biopsy of an accessible lesion at baseline and on treatment if the lesion can be biopsied with acceptable clinical risk (as judged by the Principal Investigator).\n* Measurable disease as defined by RECIST v1.1.\n* Have one of the six KRAS mutations (KRAS G12C, KRAS G12V, KRAS G12D, KRAS G12A, KRAS G13D or KRAS G12R) in vaccine expressed in tumor as defined by a Clinical Laboratory Improvement Amendments (CLIA) certified tumor or plasma based genomic testing platform performed either through a local laboratory or through the investigators' central laboratory.\n* Age ≥18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Appendix A).\n* Patients must have adequate organ and marrow function as defined below:\n\nMicroliters (mcL) Microliter (uL)\n\n* Leukocytes ≥ 3,000/mcL\n* Lymphocytes > 500/mm3\n* Absolute neutrophil count ≥ 1,000/mcL\n* Platelets ≥ 75 × 103/uL\n* Hemoglobin ≥ 8.0 g/dL\n* Total bilirubin ≤ 1.5 x ULN (< 2.0 x ULN for subjects with documented Gilbert's syndrome)\n* aspartate aminotransferase (AST) (SGOT) and alanine aminotransferase (ALT)(SGPT)≤ 2.5 × ULN (if liver metastases are present, ≤ 5 x ULN)\n* Alkaline phosphatase ≤5.0 × ULN\n* Creatinine ≤1.5 × ULN or creatinine clearance (CrCl) ≥ 40 mL/min (if using the Cockcroft-Gault formula below):\n\nFemale CrCl = (140 - age in years) x weight in kg x 0.85 / 72 x serum creatinine in mg/dL\n\nMale CrCl = (140 - age in years) x weight in kg x 1.00 / 72 x serum creatinine in mg/dL\n\n* Women of childbearing potential (WOCBP) must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin (HCG). WOCBP is defined in Section 4.6. Note: If a patient has a positive or indeterminate serum or urine pregnancy test, then an ultrasound must be done to rule out pregnancy to enroll on trial.\n* WOCBP must agree to follow instructions for method(s) of contraception from the time of enrollment for the duration of treatment with study drug(s) plus 5 half-lives of study drug(s) plus 4 weeks (duration of ovulatory cycle) for a total of 5 months post treatment completion.\n* Men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) plus 5 half-lives of study drug(s) plus 90 days (duration of sperm turnover) for a total of 7 months post-treatment completion.\n* At least one barrier method of contraception must be employed by all sexually active patients (male and female), regardless of other methods, to prevent the transfer of body fluids.\n* Ability to understand and willingness to sign a written informed consent document.\n* Last dose of adjuvant chemotherapy or radiation therapy administered within 6 months of screening date\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
        "exclusion_criteria": "* Patient is expected to require any other form of systemic or localized antineoplastic therapy while on study.\n* Any of the following procedures or medications:\n* Within 2 weeks prior to initiation of study treatment:\n\n  * Systemic or topical corticosteroids at immunosuppressive doses (> 10 mg/day of prednisone or equivalent). Inhaled or topical steroids, and adrenal replacement steroid doses ≤ 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.\n  * Palliative or adjuvant radiation or gamma knife radiosurgery.\n  * Chemotherapy\n* Within 4 weeks prior to initiation of study treatment:\n\n  * Any investigational cytotoxic drug. Exposure to any cytotoxic drug within 4 weeks or 5 half-lives (whichever is shorter) is prohibited. If 5 half-lives are shorter than 4 weeks, agreement with Investigational New Drug (IND) Sponsor is mandatory.\n  * Any investigational device\n  * Non-oncology vaccines containing live virus. Examples include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Influenza, pneumonia vaccines (polysaccharide and conjugated forms) and Corona Virus Disease 2019 (COVID-19) vaccines will be allowed, however the investigators recommend that subjects not receive any dose of vaccine within 7 days before or after the subjects' scheduled KRAS peptide vaccination.\n  * Allergen hyposensitization therapy.\n  * Growth factors, e.g. granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), erythropoietin\n  * Major surgery (excludes celiac plexus block, biliary stent placement, and other minor procedures such as dental work, skin biopsy, etc.).\n* Patients with a history of prior treatment with immunotherapy agents (including, but not limited to: Interleukin 2 (IL-2), interferon, anti-PD-L2, anti-cluster of differentiation 137 (anti-CD137), anti-oxidation (OX) 40 (anti-OX-40), anti-cluster of differentiation 40 (anti-CD40), anti-cytotoxic T-lymphocyte-associated (CTLA) antigen 4 (anti-CTLA-4), or anti-lymphocyte activating gene (LAG) 3 (anti-LAG-3) antibodies).\n\n  * Prior anti-PD-(L)1 therapy for non-metastatic NSCLC (ie/Durvalumab) is allowed if patient had received at least 6 months of therapy prior to having disease progression.\n* History of severe hypersensitivity reaction to any monoclonal antibodies or related compounds or to any of these agents' components (e.g., history of severe hypersensitivity reactions to drugs formulated with polysorbate 80).\n\n  * This includes any prior immunotherapy agents; patients having toxicity with prior anti-PD-L1 therapy requiring cessation of treatment must be excluded.\n* Untreated or symptomatic brain metastases.\n\n  * Treated brain metastases allowed on study if asymptomatic and therapy was completed at least 2 weeks prior to treatment start, and steroid dosing is as 3.2.2\n* Has an active known or suspected autoimmune disease or which has required systemic therapy in the last 2 years. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.\n* Known history of interstitial lung disease or of (non-infectious) pneumonitis that required steroids or current pneumonitis.\n* Has a pulse oximetry < 90% on room air.\n* Requires the use of home oxygen.\n* Has a known history of Human Immunodeficiency Virus (HIV) (HIV1/2 antibodies), hepatitis B, or hepatitis C infection.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness that would limit compliance with study requirements.\n* Patients who have been diagnosed with another cancer or myeloproliferative disorder in the past 5 years except for superficial bladder cancer, non-melanoma skin cancers, or a low grade prostate cancer not requiring therapy.\n* Has a diagnosis of immunodeficiency.\n* Presence of any tissue or organ allograft, regardless of need for immunosuppression, including corneal allograft. Patients with a history of allogeneic hematopoietic stem cell transplant will be excluded.\n* Any other sound medical or psychiatric reason as determined by the Investigator.\n* Patient is, at the time of signing informed consent, a regular user (including \"recreational use\") of any illicit drugs or other substance abuse (including alcohol) that could potentially interfere with adherence to study procedures or requirements.\n* Patient is unwilling or unable to follow the study schedule for any reason.\n* Patient is pregnant or breastfeeding.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have adequate organ and marrow function as defined below:",
            "criterions": [
                {
                    "exact_snippets": "adequate organ and marrow function",
                    "criterion": "organ and marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin ≤ 1.5 x ULN (< 2.0 x ULN for subjects with documented Gilbert's syndrome)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin ≤ 1.5 x ULN (< 2.0 x ULN for subjects with documented Gilbert's syndrome)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (for subjects with documented Gilbert's syndrome)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 2.0,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets ≥ 75 × 103/uL",
            "criterions": [
                {
                    "exact_snippets": "Platelets ≥ 75 × 103/uL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75000,
                                "unit": "/uL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* aspartate aminotransferase (AST) (SGOT) and alanine aminotransferase (ALT)(SGPT)≤ 2.5 × ULN (if liver metastases are present, ≤ 5 x ULN)",
            "criterions": [
                {
                    "exact_snippets": "aspartate aminotransferase (AST) (SGOT) ... ≤ 2.5 × ULN (if liver metastases are present, ≤ 5 x ULN)",
                    "criterion": "aspartate aminotransferase (AST) (SGOT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (if liver metastases are present)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT)(SGPT)≤ 2.5 × ULN (if liver metastases are present, ≤ 5 x ULN)",
                    "criterion": "alanine aminotransferase (ALT) (SGPT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (if liver metastases are present)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Microliters (mcL) Microliter (uL)",
            "criterions": [
                {
                    "exact_snippets": "Microliters (mcL) Microliter (uL)",
                    "criterion": "microliter",
                    "requirements": [
                        {
                            "requirement_type": "unit",
                            "expected_value": [
                                "mcL",
                                "uL"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least one barrier method of contraception must be employed by all sexually active patients (male and female), regardless of other methods, to prevent the transfer of body fluids.",
            "criterions": [
                {
                    "exact_snippets": "At least one barrier method of contraception must be employed by all sexually active patients (male and female), regardless of other methods",
                    "criterion": "contraception method",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "barrier method"
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": "all sexually active patients"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 100 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 100 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 100,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically- or cytologically-proven adenocarcinoma of the lung deemed to be locally advanced/unresectable or metastatic as per American Joint Committee on Cancer (AJCC) version 8, who has not received prior therapy for this stage of disease.",
            "criterions": [
                {
                    "exact_snippets": "Histologically- or cytologically-proven adenocarcinoma of the lung",
                    "criterion": "adenocarcinoma of the lung",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": [
                                "histologically-proven",
                                "cytologically-proven"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "deemed to be locally advanced/unresectable or metastatic as per American Joint Committee on Cancer (AJCC) version 8",
                    "criterion": "disease stage (lung cancer)",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced/unresectable",
                                "metastatic"
                            ]
                        },
                        {
                            "requirement_type": "staging_system",
                            "expected_value": "AJCC version 8"
                        }
                    ]
                },
                {
                    "exact_snippets": "who has not received prior therapy for this stage of disease",
                    "criterion": "prior therapy for current stage",
                    "requirements": [
                        {
                            "requirement_type": "treatment_history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alkaline phosphatase ≤5.0 × ULN",
            "criterions": [
                {
                    "exact_snippets": "Alkaline phosphatase ≤5.0 × ULN",
                    "criterion": "alkaline phosphatase",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5.0,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must have tumor lesions amenable to repeated biopsy, and patient's acceptance to have a tumor biopsy of an accessible lesion at baseline and on treatment if the lesion can be biopsied with acceptable clinical risk (as judged by the Principal Investigator).",
            "criterions": [
                {
                    "exact_snippets": "Must have tumor lesions amenable to repeated biopsy",
                    "criterion": "tumor lesions",
                    "requirements": [
                        {
                            "requirement_type": "amenability to repeated biopsy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patient's acceptance to have a tumor biopsy",
                    "criterion": "patient acceptance of tumor biopsy",
                    "requirements": [
                        {
                            "requirement_type": "acceptance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "tumor biopsy of an accessible lesion at baseline and on treatment if the lesion can be biopsied with acceptable clinical risk (as judged by the Principal Investigator)",
                    "criterion": "tumor lesion accessibility and biopsy risk",
                    "requirements": [
                        {
                            "requirement_type": "accessibility for biopsy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "acceptable clinical risk for biopsy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin ≥ 8.0 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥ 8.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age ≥18 years.",
            "criterions": [
                {
                    "exact_snippets": "Age ≥18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to understand and willingness to sign a written informed consent document.",
            "criterions": [
                {
                    "exact_snippets": "Ability to understand",
                    "criterion": "cognitive ability to understand informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to sign a written informed consent document",
                    "criterion": "willingness to sign informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine ≤1.5 × ULN or creatinine clearance (CrCl) ≥ 40 mL/min (if using the Cockcroft-Gault formula below):",
            "criterions": [
                {
                    "exact_snippets": "Creatinine ≤1.5 × ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "creatinine clearance (CrCl) ≥ 40 mL/min (if using the Cockcroft-Gault formula below)",
                    "criterion": "creatinine clearance (CrCl)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential (WOCBP) must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin (HCG). WOCBP is defined in Section 4.6. Note: If a patient has a positive or indeterminate serum or urine pregnancy test, then an ultrasound must be done to rule out pregnancy to enroll on trial.",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential (WOCBP) must have a negative serum pregnancy test",
                    "criterion": "serum pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin (HCG)",
                    "criterion": "serum pregnancy test sensitivity",
                    "requirements": [
                        {
                            "requirement_type": "minimum sensitivity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 25,
                                "unit": "IU/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "If a patient has a positive or indeterminate serum or urine pregnancy test, then an ultrasound must be done to rule out pregnancy to enroll on trial.",
                    "criterion": "ultrasound to rule out pregnancy",
                    "requirements": [
                        {
                            "requirement_type": "requirement for enrollment if pregnancy test is positive or indeterminate",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Male CrCl = (140 - age in years) x weight in kg x 1.00 / 72 x serum creatinine in mg/dL",
            "criterions": [
                {
                    "exact_snippets": "Male CrCl = (140 - age in years) x weight in kg x 1.00 / 72 x serum creatinine in mg/dL",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                },
                {
                    "exact_snippets": "age in years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "unit",
                            "expected_value": "years"
                        }
                    ]
                },
                {
                    "exact_snippets": "weight in kg",
                    "criterion": "weight",
                    "requirements": [
                        {
                            "requirement_type": "unit",
                            "expected_value": "kg"
                        }
                    ]
                },
                {
                    "exact_snippets": "serum creatinine in mg/dL",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "unit",
                            "expected_value": "mg/dL"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Lymphocytes > 500/mm3",
            "criterions": [
                {
                    "exact_snippets": "Lymphocytes > 500/mm3",
                    "criterion": "lymphocyte count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 500,
                                "unit": "mm3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count ≥ 1,000/mcL",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count ≥ 1,000/mcL",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "mcL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "• Prior therapy for early stage NSCLC allowed. Progressive disease after at least 6 months of anti-programmed death (PD) ligand therapy (anti-PD-L1 therapy) (i.e. Durvalumab) for Stage III disease is allowed.",
            "criterions": [
                {
                    "exact_snippets": "Prior therapy for early stage NSCLC allowed",
                    "criterion": "prior therapy for early stage NSCLC",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Progressive disease after at least 6 months of anti-programmed death (PD) ligand therapy (anti-PD-L1 therapy) (i.e. Durvalumab) for Stage III disease is allowed",
                    "criterion": "progressive disease after anti-PD-L1 therapy for Stage III disease",
                    "requirements": [
                        {
                            "requirement_type": "disease progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of anti-PD-L1 therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "anti-PD-L1 therapy received",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "disease stage",
                            "expected_value": "Stage III"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Appendix A).",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have one of the six KRAS mutations (KRAS G12C, KRAS G12V, KRAS G12D, KRAS G12A, KRAS G13D or KRAS G12R) in vaccine expressed in tumor as defined by a Clinical Laboratory Improvement Amendments (CLIA) certified tumor or plasma based genomic testing platform performed either through a local laboratory or through the investigators' central laboratory.",
            "criterions": [
                {
                    "exact_snippets": "Have one of the six KRAS mutations (KRAS G12C, KRAS G12V, KRAS G12D, KRAS G12A, KRAS G13D or KRAS G12R) in vaccine expressed in tumor",
                    "criterion": "KRAS mutation status",
                    "requirements": [
                        {
                            "requirement_type": "mutation_presence",
                            "expected_value": [
                                "KRAS G12C",
                                "KRAS G12V",
                                "KRAS G12D",
                                "KRAS G12A",
                                "KRAS G13D",
                                "KRAS G12R"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "as defined by a Clinical Laboratory Improvement Amendments (CLIA) certified tumor or plasma based genomic testing platform performed either through a local laboratory or through the investigators' central laboratory",
                    "criterion": "genomic testing platform certification and source",
                    "requirements": [
                        {
                            "requirement_type": "certification",
                            "expected_value": "CLIA certified"
                        },
                        {
                            "requirement_type": "sample_source",
                            "expected_value": [
                                "tumor",
                                "plasma"
                            ]
                        },
                        {
                            "requirement_type": "laboratory_type",
                            "expected_value": [
                                "local laboratory",
                                "investigators' central laboratory"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Leukocytes ≥ 3,000/mcL",
            "criterions": [
                {
                    "exact_snippets": "Leukocytes ≥ 3,000/mcL",
                    "criterion": "leukocyte count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3000,
                                "unit": "mcL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease as defined by RECIST v1.1.",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease as defined by RECIST v1.1.",
                    "criterion": "disease measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "definition standard",
                            "expected_value": "RECIST v1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Last dose of adjuvant chemotherapy or radiation therapy administered within 6 months of screening date",
            "criterions": [
                {
                    "exact_snippets": "Last dose of adjuvant chemotherapy ... administered within 6 months of screening date",
                    "criterion": "adjuvant chemotherapy administration",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Last dose of ... radiation therapy administered within 6 months of screening date",
                    "criterion": "radiation therapy administration",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) plus 5 half-lives of study drug(s) plus 90 days (duration of sperm turnover) for a total of 7 months post-treatment completion.",
            "criterions": [
                {
                    "exact_snippets": "Men who are sexually active with WOCBP",
                    "criterion": "sexual activity with women of childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) plus 5 half-lives of study drug(s) plus 90 days (duration of sperm turnover) for a total of 7 months post-treatment completion.",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Female CrCl = (140 - age in years) x weight in kg x 0.85 / 72 x serum creatinine in mg/dL",
            "criterions": [
                {
                    "exact_snippets": "Female",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "CrCl = (140 - age in years) x weight in kg x 0.85 / 72 x serum creatinine in mg/dL",
                    "criterion": "creatinine clearance (CrCl)",
                    "requirements": [
                        {
                            "requirement_type": "calculation_formula",
                            "expected_value": "(140 - age in years) x weight in kg x 0.85 / 72 x serum creatinine in mg/dL"
                        }
                    ]
                },
                {
                    "exact_snippets": "age in years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "unit",
                            "expected_value": "years"
                        }
                    ]
                },
                {
                    "exact_snippets": "weight in kg",
                    "criterion": "weight",
                    "requirements": [
                        {
                            "requirement_type": "unit",
                            "expected_value": "kg"
                        }
                    ]
                },
                {
                    "exact_snippets": "serum creatinine in mg/dL",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "unit",
                            "expected_value": "mg/dL"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* WOCBP must agree to follow instructions for method(s) of contraception from the time of enrollment for the duration of treatment with study drug(s) plus 5 half-lives of study drug(s) plus 4 weeks (duration of ovulatory cycle) for a total of 5 months post treatment completion.",
            "criterions": [
                {
                    "exact_snippets": "WOCBP must agree to follow instructions for method(s) of contraception from the time of enrollment for the duration of treatment with study drug(s) plus 5 half-lives of study drug(s) plus 4 weeks (duration of ovulatory cycle) for a total of 5 months post treatment completion.",
                    "criterion": "willingness to use contraception",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "from the time of enrollment for the duration of treatment with study drug(s) plus 5 half-lives of study drug(s) plus 4 weeks (duration of ovulatory cycle) for a total of 5 months post treatment completion"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Has a pulse oximetry < 90% on room air.",
            "criterions": [
                {
                    "exact_snippets": "pulse oximetry < 90% on room air",
                    "criterion": "pulse oximetry",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 90,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Requires the use of home oxygen.",
            "criterions": [
                {
                    "exact_snippets": "Requires the use of home oxygen",
                    "criterion": "home oxygen use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Growth factors, e.g. granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), erythropoietin",
            "criterions": [
                {
                    "exact_snippets": "Growth factors, e.g. granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), erythropoietin",
                    "criterion": "growth factors",
                    "requirements": [
                        {
                            "requirement_type": "presence/use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any of the following procedures or medications:",
            "criterions": [
                {
                    "exact_snippets": "Any of the following procedures or medications",
                    "criterion": "procedures or medications",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is pregnant or breastfeeding.",
            "criterions": [
                {
                    "exact_snippets": "Patient is pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have been diagnosed with another cancer or myeloproliferative disorder in the past 5 years except for superficial bladder cancer, non-melanoma skin cancers, or a low grade prostate cancer not requiring therapy.",
            "criterions": [
                {
                    "exact_snippets": "diagnosed with another cancer or myeloproliferative disorder in the past 5 years except for superficial bladder cancer, non-melanoma skin cancers, or a low grade prostate cancer not requiring therapy",
                    "criterion": "history of other cancer or myeloproliferative disorder",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_within_years",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "exclusion_exceptions",
                            "expected_value": [
                                "superficial bladder cancer",
                                "non-melanoma skin cancers",
                                "low grade prostate cancer not requiring therapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of severe hypersensitivity reaction to any monoclonal antibodies or related compounds or to any of these agents' components (e.g., history of severe hypersensitivity reactions to drugs formulated with polysorbate 80).",
            "criterions": [
                {
                    "exact_snippets": "History of severe hypersensitivity reaction to any monoclonal antibodies",
                    "criterion": "hypersensitivity reaction to monoclonal antibodies",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "History of severe hypersensitivity reaction ... to any ... related compounds",
                    "criterion": "hypersensitivity reaction to related compounds",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "History of severe hypersensitivity reaction ... to any of these agents' components (e.g., history of severe hypersensitivity reactions to drugs formulated with polysorbate 80)",
                    "criterion": "hypersensitivity reaction to agents' components (e.g., polysorbate 80)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a diagnosis of immunodeficiency.",
            "criterions": [
                {
                    "exact_snippets": "Has a diagnosis of immunodeficiency",
                    "criterion": "immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any investigational device",
            "criterions": [
                {
                    "exact_snippets": "Any investigational device",
                    "criterion": "investigational device",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Allergen hyposensitization therapy.",
            "criterions": [
                {
                    "exact_snippets": "Allergen hyposensitization therapy",
                    "criterion": "allergen hyposensitization therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treated brain metastases allowed on study if asymptomatic and therapy was completed at least 2 weeks prior to treatment start, and steroid dosing is as 3.2.2",
            "criterions": [
                {
                    "exact_snippets": "Treated brain metastases allowed on study if asymptomatic",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "treated"
                        },
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "asymptomatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "therapy was completed at least 2 weeks prior to treatment start",
                    "criterion": "therapy for brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "completion time before treatment start",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "steroid dosing is as 3.2.2",
                    "criterion": "steroid dosing",
                    "requirements": [
                        {
                            "requirement_type": "dosing protocol",
                            "expected_value": "as 3.2.2"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a history of prior treatment with immunotherapy agents (including, but not limited to: Interleukin 2 (IL-2), interferon, anti-PD-L2, anti-cluster of differentiation 137 (anti-CD137), anti-oxidation (OX) 40 (anti-OX-40), anti-cluster of differentiation 40 (anti-CD40), anti-cytotoxic T-lymphocyte-associated (CTLA) antigen 4 (anti-CTLA-4), or anti-lymphocyte activating gene (LAG) 3 (anti-LAG-3) antibodies).",
            "criterions": [
                {
                    "exact_snippets": "history of prior treatment with immunotherapy agents (including, but not limited to: Interleukin 2 (IL-2), interferon, anti-PD-L2, anti-cluster of differentiation 137 (anti-CD137), anti-oxidation (OX) 40 (anti-OX-40), anti-cluster of differentiation 40 (anti-CD40), anti-cytotoxic T-lymphocyte-associated (CTLA) antigen 4 (anti-CTLA-4), or anti-lymphocyte activating gene (LAG) 3 (anti-LAG-3) antibodies",
                    "criterion": "prior treatment with immunotherapy agents",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment_type",
                            "expected_value": [
                                "Interleukin 2 (IL-2)",
                                "interferon",
                                "anti-PD-L2",
                                "anti-cluster of differentiation 137 (anti-CD137)",
                                "anti-oxidation (OX) 40 (anti-OX-40)",
                                "anti-cluster of differentiation 40 (anti-CD40)",
                                "anti-cytotoxic T-lymphocyte-associated (CTLA) antigen 4 (anti-CTLA-4)",
                                "anti-lymphocyte activating gene (LAG) 3 (anti-LAG-3) antibodies"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Palliative or adjuvant radiation or gamma knife radiosurgery.",
            "criterions": [
                {
                    "exact_snippets": "Palliative or adjuvant radiation",
                    "criterion": "radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "palliative",
                                "adjuvant"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "gamma knife radiosurgery",
                    "criterion": "gamma knife radiosurgery",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Non-oncology vaccines containing live virus. Examples include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Influenza, pneumonia vaccines (polysaccharide and conjugated forms) and Corona Virus Disease 2019 (COVID-19) vaccines will be allowed, however the investigators recommend that subjects not receive any dose of vaccine within 7 days before or after the subjects' scheduled KRAS peptide vaccination.",
            "criterions": [
                {
                    "exact_snippets": "Non-oncology vaccines containing live virus. Examples include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine.",
                    "criterion": "receipt of non-oncology live virus vaccines",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Influenza, pneumonia vaccines (polysaccharide and conjugated forms) and Corona Virus Disease 2019 (COVID-19) vaccines will be allowed, however the investigators recommend that subjects not receive any dose of vaccine within 7 days before or after the subjects' scheduled KRAS peptide vaccination.",
                    "criterion": "receipt of influenza, pneumonia, or COVID-19 vaccines within 7 days before or after scheduled KRAS peptide vaccination",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 7,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is, at the time of signing informed consent, a regular user (including \"recreational use\") of any illicit drugs or other substance abuse (including alcohol) that could potentially interfere with adherence to study procedures or requirements.",
            "criterions": [
                {
                    "exact_snippets": "regular user (including \"recreational use\") of any illicit drugs",
                    "criterion": "illicit drug use",
                    "requirements": [
                        {
                            "requirement_type": "usage",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other substance abuse (including alcohol) that could potentially interfere with adherence to study procedures or requirements",
                    "criterion": "substance abuse (including alcohol)",
                    "requirements": [
                        {
                            "requirement_type": "abuse",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "potential to interfere with adherence to study procedures or requirements",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior anti-PD-(L)1 therapy for non-metastatic NSCLC (ie/Durvalumab) is allowed if patient had received at least 6 months of therapy prior to having disease progression.",
            "criterions": [
                {
                    "exact_snippets": "Prior anti-PD-(L)1 therapy for non-metastatic NSCLC (ie/Durvalumab) is allowed",
                    "criterion": "prior anti-PD-(L)1 therapy for non-metastatic NSCLC",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "if patient had received at least 6 months of therapy",
                    "criterion": "duration of prior anti-PD-(L)1 therapy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "prior to having disease progression",
                    "criterion": "timing of therapy relative to disease progression",
                    "requirements": [
                        {
                            "requirement_type": "therapy completed before disease progression",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has an active known or suspected autoimmune disease or which has required systemic therapy in the last 2 years. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.",
            "criterions": [
                {
                    "exact_snippets": "Has an active known or suspected autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "diagnosis status",
                            "expected_value": [
                                "known",
                                "suspected"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "which has required systemic therapy in the last 2 years",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "systemic therapy requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "systemic therapy time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other sound medical or psychiatric reason as determined by the Investigator.",
            "criterions": [
                {
                    "exact_snippets": "Any other sound medical or psychiatric reason as determined by the Investigator.",
                    "criterion": "medical or psychiatric reason",
                    "requirements": [
                        {
                            "requirement_type": "investigator determination",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is expected to require any other form of systemic or localized antineoplastic therapy while on study.",
            "criterions": [
                {
                    "exact_snippets": "Patient is expected to require any other form of systemic or localized antineoplastic therapy while on study.",
                    "criterion": "requirement for other systemic or localized antineoplastic therapy",
                    "requirements": [
                        {
                            "requirement_type": "expected requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "while on study"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* This includes any prior immunotherapy agents; patients having toxicity with prior anti-PD-L1 therapy requiring cessation of treatment must be excluded.",
            "criterions": [
                {
                    "exact_snippets": "any prior immunotherapy agents",
                    "criterion": "prior immunotherapy agents",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "toxicity with prior anti-PD-L1 therapy requiring cessation of treatment",
                    "criterion": "toxicity with prior anti-PD-L1 therapy",
                    "requirements": [
                        {
                            "requirement_type": "toxicity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "required cessation of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of interstitial lung disease or of (non-infectious) pneumonitis that required steroids or current pneumonitis.",
            "criterions": [
                {
                    "exact_snippets": "Known history of interstitial lung disease",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "(non-infectious) pneumonitis that required steroids",
                    "criterion": "non-infectious pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "required steroids",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "current pneumonitis",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "current",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Within 4 weeks prior to initiation of study treatment:",
            "criterions": [
                {
                    "exact_snippets": "Within 4 weeks prior to initiation of study treatment",
                    "criterion": "timing of procedure or assessment",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to initiation of study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Chemotherapy",
            "criterions": [
                {
                    "exact_snippets": "Chemotherapy",
                    "criterion": "chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness that would limit compliance with study requirements.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection",
                    "criterion": "intercurrent illness",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "ongoing or active infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": [
                                "ongoing",
                                "active"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina",
                    "criterion": "angina",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                },
                {
                    "exact_snippets": "cardiac arrhythmia",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "metastatic cancer",
                    "criterion": "metastatic cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric illness that would limit compliance with study requirements",
                    "criterion": "psychiatric illness",
                    "requirements": [
                        {
                            "requirement_type": "impact on compliance",
                            "expected_value": "would limit compliance with study requirements"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a known history of Human Immunodeficiency Virus (HIV) (HIV1/2 antibodies), hepatitis B, or hepatitis C infection.",
            "criterions": [
                {
                    "exact_snippets": "Has a known history of Human Immunodeficiency Virus (HIV) (HIV1/2 antibodies)",
                    "criterion": "Human Immunodeficiency Virus (HIV) infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis B",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis C infection",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Untreated or symptomatic brain metastases.",
            "criterions": [
                {
                    "exact_snippets": "Untreated or symptomatic brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        },
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Within 2 weeks prior to initiation of study treatment:",
            "criterions": [
                {
                    "exact_snippets": "Within 2 weeks prior to initiation of study treatment",
                    "criterion": "timing of procedure or assessment",
                    "requirements": [
                        {
                            "requirement_type": "time window before study treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery (excludes celiac plexus block, biliary stent placement, and other minor procedures such as dental work, skin biopsy, etc.).",
            "criterions": [
                {
                    "exact_snippets": "Major surgery (excludes celiac plexus block, biliary stent placement, and other minor procedures such as dental work, skin biopsy, etc.)",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any investigational cytotoxic drug. Exposure to any cytotoxic drug within 4 weeks or 5 half-lives (whichever is shorter) is prohibited. If 5 half-lives are shorter than 4 weeks, agreement with Investigational New Drug (IND) Sponsor is mandatory.",
            "criterions": [
                {
                    "exact_snippets": "Any investigational cytotoxic drug. Exposure to any cytotoxic drug within 4 weeks or 5 half-lives (whichever is shorter) is prohibited.",
                    "criterion": "exposure to cytotoxic drug",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "If 5 half-lives are shorter than 4 weeks, agreement with Investigational New Drug (IND) Sponsor is mandatory.",
                    "criterion": "agreement with IND Sponsor",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": "mandatory if 5 half-lives are shorter than 4 weeks"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is unwilling or unable to follow the study schedule for any reason.",
            "criterions": [
                {
                    "exact_snippets": "Patient is unwilling ... to follow the study schedule",
                    "criterion": "willingness to follow study schedule",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patient is ... unable to follow the study schedule",
                    "criterion": "ability to follow study schedule",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Presence of any tissue or organ allograft, regardless of need for immunosuppression, including corneal allograft. Patients with a history of allogeneic hematopoietic stem cell transplant will be excluded.",
            "criterions": [
                {
                    "exact_snippets": "Presence of any tissue or organ allograft, regardless of need for immunosuppression, including corneal allograft",
                    "criterion": "tissue or organ allograft",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of allogeneic hematopoietic stem cell transplant",
                    "criterion": "allogeneic hematopoietic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Systemic or topical corticosteroids at immunosuppressive doses (> 10 mg/day of prednisone or equivalent). Inhaled or topical steroids, and adrenal replacement steroid doses ≤ 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.",
            "criterions": [
                {
                    "exact_snippets": "Systemic or topical corticosteroids at immunosuppressive doses (> 10 mg/day of prednisone or equivalent)",
                    "criterion": "corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "route",
                            "expected_value": [
                                "systemic",
                                "topical"
                            ]
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg/day prednisone or equivalent"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Inhaled or topical steroids, and adrenal replacement steroid doses ≤ 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease",
                    "criterion": "inhaled or topical steroid use",
                    "requirements": [
                        {
                            "requirement_type": "route",
                            "expected_value": [
                                "inhaled",
                                "topical"
                            ]
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg daily prednisone equivalent"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "adrenal replacement steroid doses ≤ 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease",
                    "criterion": "adrenal replacement steroid dose",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg daily prednisone equivalent"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "are permitted in the absence of active autoimmune disease",
                    "criterion": "active autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}